select a format

Single User License
USD 2000 INR 128340
Site License
USD 4000 INR 256680
Corporate User License
USD 6000 INR 385020

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Systemic Lupus Erythematosus-Pipeline Review, H2 2015

Systemic Lupus Erythematosus-Pipeline Review, H2 2015


  • Products Id :- GMDHC7059IDB
  • |
  • Pages: 301
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Systemic Lupus Erythematosus-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Systemic Lupus Erythematosus-Pipeline Review, H2 2015', provides an overview of the Systemic Lupus Erythematosus's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Systemic Lupus Erythematosus and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Systemic Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Systemic Lupus Erythematosus pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Systemic Lupus Erythematosus Overview 11

Therapeutics Development 12

Pipeline Products for Systemic Lupus Erythematosus-Overview 12

Pipeline Products for Systemic Lupus Erythematosus-Comparative Analysis 13

Systemic Lupus Erythematosus-Therapeutics under Development by Companies 14

Systemic Lupus Erythematosus-Therapeutics under Investigation by Universities/Institutes 19

Systemic Lupus Erythematosus-Pipeline Products Glance 20

Late Stage Products 20

Clinical Stage Products 21

Early Stage Products 22

Systemic Lupus Erythematosus-Products under Development by Companies 23

Systemic Lupus Erythematosus-Products under Investigation by Universities/Institutes 28

Systemic Lupus Erythematosus-Companies Involved in Therapeutics Development 29

4SC AG 29

AbbVie Inc. 30

Ablynx NV 31

Actelion Ltd 32

AiCuris GmbH & Co. KG 33

Amgen Inc. 34

Anthera Pharmaceuticals Inc. 35

Argos Therapeutics, Inc. 36

Biogen, Inc. 37

Biotest AG 38

Bristol-Myers Squibb Company 39

Celgene Corporation 40

Cellular Biomedicine Group, Inc. 41

Chong Kun Dang Pharmaceutical Corp. 42

Eisai Co., Ltd. 43

F. Hoffmann-La Roche Ltd. 44

Genosco 45

Genovax S.r.l. 46

GlaxoSmithKline Plc 47

Hansa Medical AB 48

ImmuNext, Inc. 49

Immunomedics, Inc. 50

Immupharma Plc 51

Invion Limited 52

Johnson & Johnson 53

Kadmon Corporation, LLC 54

Karyopharm Therapeutics, Inc. 55

Kineta, Inc. 56

Lead Discovery Center GmbH 57

MacroGenics, Inc. 58

MedAnnex Ltd 59

MedImmune, LLC 60

Medsenic 61

Merck KGaA 62

Mitsubishi Tanabe Pharma Corporation 63

Neovacs SA 64

Nippon Chemiphar Co., Ltd. 65

Ocata Therapeutics, Inc. 66

Padlock Therapeutics, Inc. 67

Pfizer Inc. 68

Plexxikon Inc. 69

Principia Biopharma Inc. 70

RedHill Biopharma Ltd. 71

Redx Pharma Plc 72

Resolve Therapeutics, LLC 73

Sanofi 74

Sarepta Therapeutics, Inc. 75

SBI Biotech Co., Ltd. 76

Seattle Genetics, Inc. 77

Takeda Pharmaceutical Company Limited 78

Therapix Biosciences Ltd 79

UCB S.A. 80

Xencor, Inc. 81

XTL Biopharmaceuticals Ltd. 82

Systemic Lupus Erythematosus-Therapeutics Assessment 83

Assessment by Monotherapy Products 83

Assessment by Combination Products 84

Assessment by Target 85

Assessment by Mechanism of Action 88

Assessment by Route of Administration 91

Assessment by Molecule Type 93

Drug Profiles 95

(rifabutin + clarithromycin + clofazimine)-Drug Profile 95

abatacept-Drug Profile 98

ABBV-084-Drug Profile 101

ABS-11-Drug Profile 102

ACT-334441-Drug Profile 103

AGS-009-Drug Profile 104

AIC-284-Drug Profile 105

ALX-0061-Drug Profile 106

AMG-557-Drug Profile 108

AMG-729-Drug Profile 110

AMG-811-Drug Profile 111

anifrolumab-Drug Profile 112

Annexuzlimab-Drug Profile 114

Antibody to Inhibit ILT7 for Systemic Lupus Erythematosus-Drug Profile 115

Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease-Drug Profile 116

arsenic trioxide-Drug Profile 117

AT-791-Drug Profile 118

atacicept-Drug Profile 119

BB-004-Drug Profile 121

belimumab-Drug Profile 122

BIIB-059-Drug Profile 125

blisibimod-Drug Profile 126

brentuximab vedotin-Drug Profile 129

BT-063-Drug Profile 135

CC-220-Drug Profile 136

Cell Therapy for Autoimmune Diseases and GVHD-Drug Profile 138

CKD-506-Drug Profile 140

dalazatide-Drug Profile 141

dapirolizumab pegol-Drug Profile 143

Drug to Inhibit PAD for Autoimmune Diseases, CNS and Oncology-Drug Profile 145

E-6446-Drug Profile 147

edratide-Drug Profile 148

Endoglycosidase of Streptococcus pyogenes-Drug Profile 149

forigerimod acetate-Drug Profile 150

GNKS-356-Drug Profile 152

GX-101-Drug Profile 153

IGM-001-Drug Profile 154

IMP-10-Drug Profile 155

INV-103-Drug Profile 156

JB-6121-Drug Profile 158

KD-025-Drug Profile 159

KPT-350-Drug Profile 161

Leukothera-Drug Profile 162

lulizumab pegol-Drug Profile 164

MGD-010-Drug Profile 165

milatuzumab-Drug Profile 167

Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases-Drug Profile 169

MT-1303-Drug Profile 171

NC-2400-Drug Profile 172

NCS-613-Drug Profile 173

PF-04236921-Drug Profile 174

PRN-1008-Drug Profile 175

Recombinant Proteins for Systemic Lupus Erythematosus-Drug Profile 176

RN-486-Drug Profile 177

RO-5461111-Drug Profile 178

RSLV-132-Drug Profile 179

RSLV-133-Drug Profile 180

SAR-113244-Drug Profile 181

SBI-3150-Drug Profile 182

sifalimumab-Drug Profile 183

SM-101-Drug Profile 185

SM-934-Drug Profile 188

Small Molecule to Inhibit BTK for Cancer and Autoimmune disorders-Drug Profile 189

Small Molecule to Inhibit Immunoproteasome Subunit LMP7 for Autoimmune Disorders and Viral Infections-Drug Profile 190

Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology-Drug Profile 191

Small Molecule to Inhibit RORgammat for CNS, Autoimmune and Gastrointestinal Disorders-Drug Profile 193

Small Molecule to Inhibit SYK for Systemic Lupus Erythematosus and Rheumatoid Arthritis-Drug Profile 194

Small Molecules to Inhibit FMS Kinase for Immunology, Gastrointestinal, Respiratory and Central Nervous Sytem Diseases-Drug Profile 195

Small Molecules to Inhibit NET Formation for Sepsis and SLE-Drug Profile 196

Stem Cell Therapy for Autoimmune Diseases-Drug Profile 197

Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus-Drug Profile 198

Stem Cell Therapy for Systemic Lupus Erythematosus-Drug Profile 199

Synthetic Peptide for Systemic Lupus Erythematosus-Drug Profile 200

Synthetic Peptides for Systemic Lupus Erythematosus-Drug Profile 201

TAK-079-Drug Profile 202

TAK-114-Drug Profile 203

TAM-01-Drug Profile 205

ustekinumab-Drug Profile 206

Vaccine for Systemic Lupus Erythematosus-Drug Profile 209

Vaccine to Target Interferon Alpha for Systemic Lupus Erythematosus, Chronic Viral Infections and Dermatomyositis-Drug Profile 210

venetoclax-Drug Profile 213

VISTA-Ig-Drug Profile 216

XmAb-5871-Drug Profile 217

Y-27-Drug Profile 218

Systemic Lupus Erythematosus-Recent Pipeline Updates 219

Systemic Lupus Erythematosus-Dormant Projects 279

Systemic Lupus Erythematosus-Discontinued Products 284

Systemic Lupus Erythematosus-Product Development Milestones 285

Featured News & Press Releases 285

Appendix 294

Methodology 294

Coverage 294

Secondary Research 294

Primary Research 294

Expert Panel Validation 294

Contact Us 294

Disclaimer 295

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, H2 2015 18

Number of Products under Development for Systemic Lupus Erythematosus-Comparative Analysis, H2 2015 19

Number of Products under Development by Companies, H2 2015 21

Number of Products under Development by Companies, H2 2015 (Contd..1) 22

Number of Products under Development by Companies, H2 2015 (Contd..2) 23

Number of Products under Development by Companies, H2 2015 (Contd..3) 24

Number of Products under Investigation by Universities/Institutes, H2 2015 25

Comparative Analysis by Late Stage Development, H2 2015 26

Comparative Analysis by Clinical Stage Development, H2 2015 27

Comparative Analysis by Early Stage Development, H2 2015 28

Products under Development by Companies, H2 2015 29

Products under Development by Companies, H2 2015 (Contd..1) 30

Products under Development by Companies, H2 2015 (Contd..2) 31

Products under Development by Companies, H2 2015 (Contd..3) 32

Products under Development by Companies, H2 2015 (Contd..4) 33

Products under Investigation by Universities/Institutes, H2 2015 34

Systemic Lupus Erythematosus-Pipeline by 4SC AG, H2 2015 35

Systemic Lupus Erythematosus-Pipeline by AbbVie Inc., H2 2015 36

Systemic Lupus Erythematosus-Pipeline by Ablynx NV, H2 2015 37

Systemic Lupus Erythematosus-Pipeline by Actelion Ltd, H2 2015 38

Systemic Lupus Erythematosus-Pipeline by AiCuris GmbH & Co. KG, H2 2015 39

Systemic Lupus Erythematosus-Pipeline by Amgen Inc., H2 2015 40

Systemic Lupus Erythematosus-Pipeline by Anthera Pharmaceuticals Inc., H2 2015 41

Systemic Lupus Erythematosus-Pipeline by Argos Therapeutics, Inc., H2 2015 42

Systemic Lupus Erythematosus-Pipeline by Biogen, Inc., H2 2015 43

Systemic Lupus Erythematosus-Pipeline by Biotest AG, H2 2015 44

Systemic Lupus Erythematosus-Pipeline by Bristol-Myers Squibb Company, H2 2015 45

Systemic Lupus Erythematosus-Pipeline by Celgene Corporation, H2 2015 46

Systemic Lupus Erythematosus-Pipeline by Cellular Biomedicine Group, Inc., H2 2015 47

Systemic Lupus Erythematosus-Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 48

Systemic Lupus Erythematosus-Pipeline by Eisai Co., Ltd., H2 2015 49

Systemic Lupus Erythematosus-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 50

Systemic Lupus Erythematosus-Pipeline by Genosco, H2 2015 51

Systemic Lupus Erythematosus-Pipeline by Genovax S.r.l., H2 2015 52

Systemic Lupus Erythematosus-Pipeline by GlaxoSmithKline Plc, H2 2015 53

Systemic Lupus Erythematosus-Pipeline by Hansa Medical AB, H2 2015 54

Systemic Lupus Erythematosus-Pipeline by ImmuNext, Inc., H2 2015 55

Systemic Lupus Erythematosus-Pipeline by Immunomedics, Inc., H2 2015 56

Systemic Lupus Erythematosus-Pipeline by Immupharma Plc, H2 2015 57

Systemic Lupus Erythematosus-Pipeline by Invion Limited, H2 2015 58

Systemic Lupus Erythematosus-Pipeline by Johnson & Johnson, H2 2015 59

Systemic Lupus Erythematosus-Pipeline by Kadmon Corporation, LLC, H2 2015 60

Systemic Lupus Erythematosus-Pipeline by Karyopharm Therapeutics, Inc., H2 2015 61

Systemic Lupus Erythematosus-Pipeline by Kineta, Inc., H2 2015 62

Systemic Lupus Erythematosus-Pipeline by Lead Discovery Center GmbH, H2 2015 63

Systemic Lupus Erythematosus-Pipeline by MacroGenics, Inc., H2 2015 64

Systemic Lupus Erythematosus-Pipeline by MedAnnex Ltd, H2 2015 65

Systemic Lupus Erythematosus-Pipeline by MedImmune, LLC, H2 2015 66

Systemic Lupus Erythematosus-Pipeline by Medsenic, H2 2015 67

Systemic Lupus Erythematosus-Pipeline by Merck KGaA, H2 2015 68

Systemic Lupus Erythematosus-Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 69

Systemic Lupus Erythematosus-Pipeline by Neovacs SA, H2 2015 70

Systemic Lupus Erythematosus-Pipeline by Nippon Chemiphar Co., Ltd., H2 2015 71

Systemic Lupus Erythematosus-Pipeline by Ocata Therapeutics, Inc., H2 2015 72

Systemic Lupus Erythematosus-Pipeline by Padlock Therapeutics, Inc., H2 2015 73

Systemic Lupus Erythematosus-Pipeline by Pfizer Inc., H2 2015 74

Systemic Lupus Erythematosus-Pipeline by Plexxikon Inc., H2 2015 75

Systemic Lupus Erythematosus-Pipeline by Principia Biopharma Inc., H2 2015 76

Systemic Lupus Erythematosus-Pipeline by RedHill Biopharma Ltd., H2 2015 77

Systemic Lupus Erythematosus-Pipeline by Redx Pharma Plc, H2 2015 78

Systemic Lupus Erythematosus-Pipeline by Resolve Therapeutics, LLC, H2 2015 79

Systemic Lupus Erythematosus-Pipeline by Sanofi, H2 2015 80

Systemic Lupus Erythematosus-Pipeline by Sarepta Therapeutics, Inc., H2 2015 81

Systemic Lupus Erythematosus-Pipeline by SBI Biotech Co., Ltd., H2 2015 82

Systemic Lupus Erythematosus-Pipeline by Seattle Genetics, Inc., H2 2015 83

Systemic Lupus Erythematosus-Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 84

Systemic Lupus Erythematosus-Pipeline by Therapix Biosciences Ltd, H2 2015 85

Systemic Lupus Erythematosus-Pipeline by UCB S.A., H2 2015 86

Systemic Lupus Erythematosus-Pipeline by Xencor, Inc., H2 2015 87

Systemic Lupus Erythematosus-Pipeline by XTL Biopharmaceuticals Ltd., H2 2015 88

Assessment by Monotherapy Products, H2 2015 89

Assessment by Combination Products, H2 2015 90

Number of Products by Stage and Target, H2 2015 92

Number of Products by Stage and Mechanism of Action, H2 2015 95

Number of Products by Stage and Route of Administration, H2 2015 98

Number of Products by Stage and Molecule Type, H2 2015 100

Systemic Lupus Erythematosus Therapeutics-Recent Pipeline Updates, H2 2015 225

Systemic Lupus Erythematosus-Dormant Projects, H2 2015 285

Systemic Lupus Erythematosus-Dormant Projects (Contd..1), H2 2015 286

Systemic Lupus Erythematosus-Dormant Projects (Contd..2), H2 2015 287

Systemic Lupus Erythematosus-Dormant Projects (Contd..3), H2 2015 288

Systemic Lupus Erythematosus-Dormant Projects (Contd..4), H2 2015 289

Systemic Lupus Erythematosus-Discontinued Products, H2 2015 290

List of Figures

Number of Products under Development for Systemic Lupus Erythematosus, H2 2015 18

Number of Products under Development for Systemic Lupus Erythematosus-Comparative Analysis, H2 2015 19

Number of Products under Development by Companies, H2 2015 20

Number of Products under Investigation by Universities/Institutes, H2 2015 25

Comparative Analysis by Clinical Stage Development, H2 2015 27

Comparative Analysis by Early Stage Products, H2 2015 28

Assessment by Monotherapy Products, H2 2015 89

Number of Products by Top 10 Targets, H2 2015 91

Number of Products by Stage and Top 10 Targets, H2 2015 91

Number of Products by Top 10 Mechanism of Actions, H2 2015 94

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 94

Number of Products by Routes of Administration, H2 2015 97

Number of Products by Stage and Routes of Administration, H2 2015 97

Number of Products by Top 10 Molecule Types, H2 2015 99

Number of Products by Stage and Top 10 Molecule Types, H2 2015 99

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AbbVie Inc.

Ablynx NV

Actelion Ltd

AiCuris GmbH & Co. KG

Amgen Inc.

Anthera Pharmaceuticals Inc.

Argos Therapeutics, Inc.

Biogen, Inc.

Biotest AG

Bristol-Myers Squibb Company

Celgene Corporation

Cellular Biomedicine Group, Inc.

Chong Kun Dang Pharmaceutical Corp.

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

Genosco

Genovax S.r.l.

GlaxoSmithKline Plc

Hansa Medical AB

ImmuNext, Inc.

Immunomedics, Inc.

Immupharma Plc

Invion Limited

Johnson & Johnson

Kadmon Corporation, LLC

Karyopharm Therapeutics, Inc.

Kineta, Inc.

Lead Discovery Center GmbH

MacroGenics, Inc.

MedAnnex Ltd

MedImmune, LLC

Medsenic

Merck KGaA

Mitsubishi Tanabe Pharma Corporation

Neovacs SA

Nippon Chemiphar Co., Ltd.

Ocata Therapeutics, Inc.

Padlock Therapeutics, Inc.

Pfizer Inc.

Plexxikon Inc.

Principia Biopharma Inc.

RedHill Biopharma Ltd.

Redx Pharma Plc

Resolve Therapeutics, LLC

Sanofi

Sarepta Therapeutics, Inc.

SBI Biotech Co., Ltd.

Seattle Genetics, Inc.

Takeda Pharmaceutical Company Limited

Therapix Biosciences Ltd

UCB S.A.

Xencor, Inc.

XTL Biopharmaceuticals Ltd.

Systemic Lupus Erythematosus Therapeutic Products under Development, Key Players in Systemic Lupus Erythematosus Therapeutics, Systemic Lupus Erythematosus Pipeline Overview, Systemic Lupus Erythematosus Pipeline, Systemic Lupus Erythematosus Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com